Published in Int J Cancer on April 30, 2016
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
Real-time imaging reveals the single steps of brain metastasis formation. Nat Med (2009) 3.95
Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature (2015) 3.83
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet (2015) 3.13
Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling. Cancer Cell (2015) 2.94
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov (2013) 2.61
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol (2004) 2.50
A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer (2003) 2.37
Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol (2004) 2.36
Prognostic factors for survival in melanoma patients with brain metastases. Cancer (2010) 2.23
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res (2009) 2.21
Carcinomatous meningitis: Leptomeningeal metastases in solid tumors. Surg Neurol Int (2013) 2.12
Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol (2012) 1.93
BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res (2014) 1.89
Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer (1998) 1.81
Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol (2008) 1.73
Perineural spread of malignant melanoma of the head and neck: clinical and imaging features. AJNR Am J Neuroradiol (2004) 1.65
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol (2014) 1.55
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov (2015) 1.51
Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment. Curr Cancer Ther Rev (2011) 1.40
Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res (2011) 1.35
Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res (2010) 1.31
Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther (2012) 1.26
Beyond BRAF: where next for melanoma therapy? Br J Cancer (2014) 1.26
Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther (2012) 1.25
A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol (2008) 1.23
Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro Oncol (2008) 1.19
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med (2013) 1.19
Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother (2002) 1.15
Ultrastructure of the human spinal arachnoid mater and dura mater. J Anat (1996) 1.13
Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report. J Med Case Rep (2012) 1.09
Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report. Melanoma Res (2013) 1.03
Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases. Anticancer Res (2009) 1.03
Leptomeningeal carcinomatosis. How does cancer reach the pia-arachnoid? Cancer (1983) 1.02
Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PLoS One (2013) 1.02
Detection and quantification of CSF malignant cells by the CellSearch technology in patients with melanoma leptomeningeal metastasis. Med Oncol (2013) 1.02
Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma. Melanoma Res (2015) 1.01
Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res (2010) 1.01
Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa. J Neurooncol (2013) 1.01
AKT1 Activation Promotes Development of Melanoma Metastases. Cell Rep (2015) 1.00
Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab. J Neurol (2012) 1.00
A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer (2002) 0.96
BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clin Cancer Res (2015) 0.95
BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape. J Invest Dermatol (2015) 0.91
Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. Muscle Nerve (2013) 0.89
Vemurafenib for leptomeningeal melanomatosis. J Clin Oncol (2013) 0.87
Novel treatments for melanoma brain metastases. Cancer Control (2013) 0.87
Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases. Pigment Cell Melanoma Res (2015) 0.86
Treatment of melanoma brain metastases: a new paradigm. Cancer J (2012) 0.86
Leptomeningeal carcinomatosis from breast cancer treated with intrathecal topotecan with concomitant intravenous eribulin. J Clin Neurosci (2013) 0.85
Molecular profiling of tumor cells in cerebrospinal fluid and matched primary tumors from metastatic breast cancer patients with leptomeningeal carcinomatosis. Cancer Res (2013) 0.84
Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal melanoma. Clin Cancer Res (2001) 0.84
Leptomeningeal metastasis in melanoma: a prospective clinical study of nine patients. In Vivo (2012) 0.83
Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors. J Neurooncol (2012) 0.82
Complete Cytologic Remission of V600E BRAF-Mutant Melanoma-Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib. J Clin Oncol (2014) 0.79
Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report. Cancer Immunol Res (2015) 0.79
Primary leptomeningeal melanoma mimicking meningitis: a case report and literature review. J Clin Oncol (2014) 0.78
Leptomeningeal melanomatosis: stabilization of disease due to radiation, temozolomide and intrathecal liposomal cytarabine. Acta Oncol (2011) 0.78
Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report. BMC Cancer (2015) 0.78
Vemurafenib in leptomeningeal carcinomatosis from melanoma: a case report of near-complete response and prolonged survival. Melanoma Res (2016) 0.77
Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature. J Oncol Pharm Pract (2015) 0.76